- The comparative study in different cell models showed that PHH, hSKP or a combination of both as the most sensitive models for determining anti-NASH responses- PPAR agonists produced differential responses regarding the reduced expression of profibrotic genes, inflammatory chemokine production, and fat accumulation, allowing creating a score system to grade potencies- Elafibranor and saroglitazar showed the strongest anti-NASH properties. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.